Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
Identifieur interne : 000508 ( Main/Exploration ); précédent : 000507; suivant : 000509Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
Auteurs : Ayman Chit [Canada] ; Julie Roiz [Royaume-Uni] ; Benjamin Briquet [France] ; David P. Greenberg [États-Unis]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice, Analyse de survie, Coûts des soins de santé, Femelle, Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains, Incidence, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (économie), États-Unis d'Amérique (épidémiologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Grippe humaine, Vaccins antigrippaux.
- économie : Grippe humaine, Vaccins antigrippaux.
- épidémiologie : Grippe humaine, États-Unis d'Amérique.
- Analyse coût-bénéfice, Analyse de survie, Coûts des soins de santé, Femelle, Grippe humaine, Humains, Incidence, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Cost-Benefit Analysis, Female, Health Care Costs, Humans, Incidence, Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza Vaccines (immunology), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male, Survival Analysis, United States (epidemiology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , economics : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- geographic , epidemiology : United States.
- economics : Influenza, Human.
- epidemiology : Influenza, Human.
- immunology : Influenza, Human.
- prevention & control : Influenza, Human.
- Aged, Aged, 80 and over, Cost-Benefit Analysis, Female, Health Care Costs, Humans, Incidence, Male, Survival Analysis.
Abstract
Seniors are particularly vulnerable to complications resulting from influenza infection. Numerous influenza vaccines are available to immunize US seniors, and practitioners must decide which product to use. Options include trivalent and quadrivalent standard-dose inactivated influenza vaccines (IIV3 and IIV4 respectively), as well as a high-dose IIV3 (HD). Our research examines the public health impact, budget impact, and cost-utility of HD versus IIV3 and IIV4 for immunization of US seniors 65 years of age and older.
DOI: 10.1016/j.vaccine.2014.10.079
PubMed: 25444791
Affiliations:
- Canada, France, Royaume-Uni, États-Unis
- Angleterre, Grand Londres, Pennsylvanie, Île-de-France
- Londres, Paris
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A09
- to stream PubMed, to step Curation: 000A09
- to stream PubMed, to step Checkpoint: 000A09
- to stream Ncbi, to step Merge: 004080
- to stream Ncbi, to step Curation: 004080
- to stream Ncbi, to step Checkpoint: 004080
- to stream Main, to step Merge: 000508
- to stream Main, to step Curation: 000508
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.</title><author><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi Pasteur, Toronto, Ontario, Canada; University of Toronto Faculty of Pharmacy, Toronto, ON, Canada. Electronic address: Ayman.chit@sanofipasteur.com.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sanofi Pasteur, Toronto, Ontario, Canada; University of Toronto Faculty of Pharmacy, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Roiz, Julie" sort="Roiz, Julie" uniqKey="Roiz J" first="Julie" last="Roiz">Julie Roiz</name><affiliation wicri:level="3"><nlm:affiliation>Creativ-Ceutical Ltd, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Creativ-Ceutical Ltd, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Briquet, Benjamin" sort="Briquet, Benjamin" uniqKey="Briquet B" first="Benjamin" last="Briquet">Benjamin Briquet</name><affiliation wicri:level="3"><nlm:affiliation>Creativ-Ceutical SARL, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Creativ-Ceutical SARL, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P" last="Greenberg">David P. Greenberg</name><affiliation wicri:level="2"><nlm:affiliation>Sanofi Pasteur, Swiftwater, PA, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sanofi Pasteur, Swiftwater, PA, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25444791</idno><idno type="pmid">25444791</idno><idno type="doi">10.1016/j.vaccine.2014.10.079</idno><idno type="wicri:Area/PubMed/Corpus">000A09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A09</idno><idno type="wicri:Area/PubMed/Curation">000A09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A09</idno><idno type="wicri:Area/PubMed/Checkpoint">000A09</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A09</idno><idno type="wicri:Area/Ncbi/Merge">004080</idno><idno type="wicri:Area/Ncbi/Curation">004080</idno><idno type="wicri:Area/Ncbi/Checkpoint">004080</idno><idno type="wicri:Area/Main/Merge">000508</idno><idno type="wicri:Area/Main/Curation">000508</idno><idno type="wicri:Area/Main/Exploration">000508</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.</title><author><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi Pasteur, Toronto, Ontario, Canada; University of Toronto Faculty of Pharmacy, Toronto, ON, Canada. Electronic address: Ayman.chit@sanofipasteur.com.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sanofi Pasteur, Toronto, Ontario, Canada; University of Toronto Faculty of Pharmacy, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Roiz, Julie" sort="Roiz, Julie" uniqKey="Roiz J" first="Julie" last="Roiz">Julie Roiz</name><affiliation wicri:level="3"><nlm:affiliation>Creativ-Ceutical Ltd, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Creativ-Ceutical Ltd, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Briquet, Benjamin" sort="Briquet, Benjamin" uniqKey="Briquet B" first="Benjamin" last="Briquet">Benjamin Briquet</name><affiliation wicri:level="3"><nlm:affiliation>Creativ-Ceutical SARL, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Creativ-Ceutical SARL, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P" last="Greenberg">David P. Greenberg</name><affiliation wicri:level="2"><nlm:affiliation>Sanofi Pasteur, Swiftwater, PA, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sanofi Pasteur, Swiftwater, PA, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cost-Benefit Analysis</term><term>Female</term><term>Health Care Costs</term><term>Humans</term><term>Incidence</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (economics)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Survival Analysis</term><term>United States (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Analyse de survie</term><term>Coûts des soins de santé</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Incidence</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (économie)</term><term>États-Unis d'Amérique (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cost-Benefit Analysis</term><term>Female</term><term>Health Care Costs</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Analyse de survie</term><term>Coûts des soins de santé</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Incidence</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Seniors are particularly vulnerable to complications resulting from influenza infection. Numerous influenza vaccines are available to immunize US seniors, and practitioners must decide which product to use. Options include trivalent and quadrivalent standard-dose inactivated influenza vaccines (IIV3 and IIV4 respectively), as well as a high-dose IIV3 (HD). Our research examines the public health impact, budget impact, and cost-utility of HD versus IIV3 and IIV4 for immunization of US seniors 65 years of age and older.</div></front></TEI><affiliations><list><country><li>Canada</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Pennsylvanie</li><li>Île-de-France</li></region><settlement><li>Londres</li><li>Paris</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Chit, Ayman" sort="Chit, Ayman" uniqKey="Chit A" first="Ayman" last="Chit">Ayman Chit</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Roiz, Julie" sort="Roiz, Julie" uniqKey="Roiz J" first="Julie" last="Roiz">Julie Roiz</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Briquet, Benjamin" sort="Briquet, Benjamin" uniqKey="Briquet B" first="Benjamin" last="Briquet">Benjamin Briquet</name></region></country><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Greenberg, David P" sort="Greenberg, David P" uniqKey="Greenberg D" first="David P" last="Greenberg">David P. Greenberg</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000508 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000508 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25444791
|texte= Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25444791" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |